CredibleMeds

CredibleMeds is an online database of independent information regarding the safe use of medicines.[1] The database, launched in 2009, helps to detect serious drug-drug interactions, especially those associated with QT prolongation or the potentially lethal arrhythmia, torsades de pointes (TdP).[2][3][4][5][6] It also assists with measurement of the quality of healthcare delivery for the Centers for Medicare and Medicaid Services, and aids in the management of patients with inherited channelopathies.[7][8]

The overall goal of CredibleMeds is to support efforts to improve the safe use of medicines.

History

The Arizona Center for Education and Research on Therapeutics (AZCERT) maintains the CredibleMeds database. Founded in 2000 at the University of Arizona as part of a network of 14 federally-funded CERTs,[9] AZCERT became a separate non-profit corporation in 2012 funded by the US Food and Drug Administration (FDA), research grants, and charitable contributions. AZCERT focuses on drugs and drug–drug interactions, especially those that cause QT prolongation and Torsades de Pointes (TdP) arrhythmia, and provides its research and its lists of drugs[10] free of charge to the public, healthcare providers, and researchers for personal, professional, and non-commercial purposes. To maintain the independence of its work, AZCERT does not receive funding from companies that have a commercial interest in medications.

Adverse drug event analysis

AZCERT developed the Adverse Drug Event Causality Analysis (ADECA) to evaluate drugs for their risk of causing QT prolongation and TdP.[11] As part of its ADECA reviews, AZCERT includes drugs marketed outside the United States, especially in Europe, Japan, and Canada. In addition to their use to inform healthcare decision making, CredibleMeds’ lists of drugs have been used in research published in more than 50 scientific articles.[12][13][14][15]

References
  1. Woosley RL, Black K, Heise CW, Romero K. CredibleMeds.org: What does it offer? Trends in Cardiovascular Medicine. 2017;28.2:94-99.
  2. Schepker K. “CredibleMeds” – New Private-Public Project Aims to Reduce Antibiotic Side-Effects. Holistic Primary Care-News for Health & Healing. Published 19 October 2016. https://holisticprimarycare.net/topics/topics-h-n/holistech/1837-crediblemeds-new-private-public-collaboration-aims-to-reduce-inappropriate-antibiotic-use.html (accessed 18 June 2019).
  3. Poluzzi E, Raschi E, Diemberger I, De Ponti F. Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice. Drug Safety. 2017;40:461-4.
  4. CredibleMeds. The Journal of QT informatics. http://qtinformatics.com/crediblemeds/ Archived 2019-06-16 at the Wayback Machine (accessed 18 June 2019).
  5. CredibleMeds Filtered QTDrug List. Continuing Pharmacy Professional Development. The University of British Columbia Faculty of Pharmaceutical Sciences. https://cpd.pharmacy.ubc.ca/sites/cpd.pharmacy.ubc.ca/files/uploads/Update_2016/DLi_WS4_Drug_Interact/CredibleMeds%20Filtered%20QTDrug%20List%20Feb%2021%2C%202016.pdf (accessed 18 June 2019).
  6. Drugs That Prolong the QT Interval and/or Induce Torsades de Pointes. Sudden Arrhythmia Death Syndromes (SADS) Foundation. https://www.sads.org/living-with-sads/Drugs-to-Avoid#.XQZzNY97nIU (accessed 18 June 2019).
  7. Al-Khatib SM, LaPointe NM, Kramer JM, Califf, RM. What Clinicians Should Know About the QT Interval. Journal of American Medicine Association. 2003;289:2120-7.
  8. LaPointe NM, Al-Khatib SM, Kramer JM, Califf RM. [https://doi.org/10.1046/j.1542-474X.2003.08211.x Knowledge Deficits Related to the QT Interval Could Affect Patient Safety. Annals of Noninvasive Electrocardiology. 2003;8:157-60.
  9. Reidenberg MM. Centers for Education and Research in Therapeutics. Clinical Pharmacology and Therapeutics (2000) 68:109-10.
  10. QTdrugs.org
  11. Schwartz PJ, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. Journal of the American College of Cardiology (2016) 67.13:1639-1650.
  12. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363–1372. doi:10.1136/heart.89.11.1363
  13. Miranda DG, McMain CL, Smith AJ. Medication-induced QT-interval prolongation and torsades de pointes. US Pharm. 2011;36(2):HS-2-HS-8.
  14. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Annals of Internal Medicine. 2009;150:387–395. doi: 10.7326/0003-4819-150-6-200903170-00103
  15. Medsafe. Drug-induced QT prolongation and torsades de pointes - the facts. Prescriber Update 2010;31(4): 27-29. https://www.medsafe.govt.nz/profs/PUArticles/PDF/Prescriber%20Update%20Dec%202010.pdf (accessed 18 June 2019).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.